Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature

Heart and Vessels

Volumn 29, Issue 4, 2014, Pages 532-541

  Shida, Takuya ^a   Nozawa, Takashi ^a   Sobajima, Mitsuo ^a   Ihori, Hiroyuki ^a   Matsuki, Akira ^a   Inoue, Hiroshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Coronary microvessels; Oxidative stress; Statin; Streptozotocin

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MEMBRANE PROTEIN; MESSENGER RNA; OXIDASE SUBUNIT P22 PHOX; OXIDASE SUBUNIT P91 PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; VASCULOTROPIN; 8-ISOPROSTAGLANDIN E2; ACTIN; ANTIOXIDANT; CD31 ANTIGEN; CYBB PROTEIN, RAT; HIF1A PROTEIN, RAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; ISOPROSTANE DERIVATIVE; MONOUNSATURATED FATTY ACID; NOS3 PROTEIN, RAT; P22-PHOX PROTEIN, RAT; PROSTAGLANDIN E2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMOOTH MUSCLE ACTIN, RAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ANTIOXIDANT ASSAY; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MONITORING; CELL DENSITY; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION; HEART HEMODYNAMICS; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANGIOGENESIS; ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE PRESSURE; METABOLISM; MICROVASCULATURE; PATHOPHYSIOLOGY; WISTAR RAT;

ACTINS; ANIMALS; ANTIGENS, CD31; ANTIOXIDANTS; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DINOPROSTONE; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLES; ISOPROSTANES; MALE; MEMBRANE GLYCOPROTEINS; MICROVESSELS; NADPH OXIDASE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RATS, WISTAR; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84904088103     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0402-6     Document Type: Article

References (53)

1. Aragno M, Mastrocola R, Medana C, Catalano MG, Vercellinatto I, Danni OT, Boccuzzi G (2006) Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology 147:5967-5974 (Pubitemid 44833515)
2. Ye G, Metreveli NS, Ren J, Epstein PN (2003) Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species protection. Diabetes 52:777-783 (Pubitemid 36323586)
3. Brownlee M, Cerami A, Viassara H (1988) Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 4:437-451
4. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939-1945
5. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790 (Pubitemid 30212409)
6. Yagihashi S, Yamagishi S, Wada R, Baba M, Hohman TC, Yabe-Nishimura C, Kokai Y (2001) Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 124:2448-2458 (Pubitemid 33134934)
7. Pop-Busui R, Kirkwood I, Schmid H, Marinescu V, Schroeder J, Larkin D, Yamada E, Raffel DM, Stevens MJ (2004) Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 44:2368-2374 (Pubitemid 39647612)
8. Yokoyama I, Momomura S, Ohtake T, Yonekura K, Nishikawa J, Sasaki Y, Omata M (1997) Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 15:1472-1477 (Pubitemid 27486464)
9. Yokoyama I, Yonekura K, Ohtake T, Yang W, Shin WS, Yamada N, Ohtomo K, Nagai R (2000) Coronary microangiopathy in type 2 diabetic patients: relation to glycemic control, sex, and microvascular angina rather than to coronary artery disease. J Nucl Med 41:978-985 (Pubitemid 30396644)
10. Han B, Baliga R, Huang H, Giannone PJ, Bauer JA (2009) Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 297:H829-H835
11. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, Kirchmair R, Bahlman F, Walter D, Curry C, Hanley A, Isner JM, Losordo DW (2005) Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111:2073-2085 (Pubitemid 40577902)
12. Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
13. Sowers JR (2003) Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol 91:14B-22B
14. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010
15. Laufs U, Liao JK (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273:24266-24271 (Pubitemid 28435775)
16. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaza M, Liao JK (2001) Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108:1429-1437 (Pubitemid 33091980)
17. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108:391-397 (Pubitemid 32730785)
18. Suzumura K, Tanaka K, Yasuhara M, Narita H (2000) Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein. Biol Pharm Bull 23:873-878 (Pubitemid 30484388)
19. Sobajima M, Nozawa T, Shida T, Ohori T, Suzuki T, Matsuki A, Inoue H (2011) Repeated sauna therapy attenuates ventricular remodeling after myocardial infarction in rats by increasing coronary vascularity of noninfarcted myocardium. Am J Physiol Heart Circ Physiol 301:H548-H554
20. Matsuki A, Nozawa T, Igarashi N, Sobajima M, Ohori T, Suzuki T, Fujii N, Igawa A, Inoue H (2010) Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circ J 74:468-475
21. Ohashi N, Yoshikawa M (2000) Rapid and sensitive quantification of 8-isoprostaglandin F2α in human plasma and urine by lipid chromatography-electrospray ionization mass spectrometry. J Chromatogr B 746:17-24
22. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadán-Diehl C, Goldberg IJ (2007) Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 100:1415-1427 (Pubitemid 46834754)
23. Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A (2009) Diabetic cardiomyopathy. Clin Sci 116:741-760
24. Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213-3223 (Pubitemid 47012236)
25. Poornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 17:596-605
26. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51:1938-1948 (Pubitemid 34564309)
27. Korte FS, Mokelke EA, Sturek M, McDonald KS (2005) Exercise improves impaired ventricular function and alterations of cardiac myofibrillar proteins in diabetic dyslipidemic pigs. J Appl Physiol 98:461-467 (Pubitemid 40129952)
28. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Escher F, Bücker-Gärtner C, Spillmann F, Noutsias M, Riad A, Schultheiss HP, Tschöpe C (2007) Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56:1834-1841 (Pubitemid 47025453)
29. Fein FS, Sonnenblick EH (1985) Diabetic cardiomyopathy. Prog Cardiovasc Dis 27:255-270 (Pubitemid 15158896)
30. Crespo MJ, Zalacain J, Dunbar DC, Arocho L (2008) Cardiac oxidative stress is elevated at the onset of dilated cardiomyopathy in streptozotocin-diabetic rats. J Cardiovasc Pharmacol Ther 13:64-71 (Pubitemid 351238292)
31. 2α and platelet activation in diabetes mellitus. Effects of improved metabolic control and vitamin E supplementation. Circulation 99:224-229
32. Bayraktutan U, Blayney L, Shah AM (2000) Molecular characterization and localization of the NAD(P)H oxidase components gp91phox and p22phox in endothelial cells. Arterioscler Thromb Vasc Biol 20:1903-1911 (Pubitemid 30644639)
33. Van Heerebeek L, Meischl C, Stooker W, Meijer CJ, Niessen HW, Roos D (2002) NADPH oxidase(s): new source(s) of reactive oxygen species in the vascular system? J Clin Pathol 55:561-568
34. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 103:421-427
35. Pratico D, Lee VM, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12:1777-1783 (Pubitemid 28553673)
36. Beckman JA, Goldfine AB, Gordon MB, Creager M (2001) Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 103:1618-1623 (Pubitemid 32246607)
37. El-Azab MF, Hazem RM, Moustafa YM (2012) Role of simvastatin and/or antioxidant vitamins in the therapeutic angiogenesis in experimental diabetic hindlimb ischemia: effects on capillary density, angiogenesis markers, and oxidative stress. Eur J Pharmacol 690:31-41
38. Erös B, Snipes JA, Tulbert CD, Katakam P, Miller AW, Busija DW (2006) Rosuvastatin improves cerebrovascular function in Zuker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am J Physiol Heart Circ Physiol 290:H1264-H1270
39. - with aortic remodeling induced by pressure overload. Am J Physiol Heart Circ Physiol 281:H655-H660
40. Cai S, Khoo J, Mussa S, Alp NJ, Channon KM (2005) Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48:1933-1940 (Pubitemid 41317851)
41. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL (2002) Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105:373-379 (Pubitemid 34106188)
42. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaaker MB, Verseyden C, de Boer HC (2004) Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53:195-199 (Pubitemid 38044715)
43. Emanueli C, Monopoli A, Kraenkel N, Meloni M, Gadau S, Campesi I, Ongini E, Madeddu P (2007) Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb ischemia in type-1 diabetic mice. Br J Pharmacol 150:873-882 (Pubitemid 46536620)
44. Kimura H, Esumi H (2003) Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol 50:49-59 (Pubitemid 37034227)
45. Thirunavukkarasu M, Selvaraju V, Dunna NR, Foye JLC, Joshi M, Otani H, Maulik N (2013) Simvastatin treatment inhibits hypoxia inducible factor 1-alpha (HIF-1 alpha)-prolyl-4-hydroxylase 3 (PHD-3) and increases angiogenesis after myocardial infarction in streptozotocin-induced diabetic rat. Int J Cardiol (Epub ahead of print)
46. Roy H, Bhardwaj S, Ylä-Herttuala S (2006) Biology of vascular endothelial growth factors. FEBS Lett 580:2879-2887 (Pubitemid 43729175)
47. McDonagh PF, Hokama JY (2000) Microvascular perfusion and transport in the diabetic heart. Microcirculation 7:163-181
48. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, Westermann D, Hilfiker-Kleiner D, Noutsias M, Laufs U, Schulthesis HP, Tschöpe C (2007) Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50:1977-1986 (Pubitemid 47222844)
49. Bambace C, Sepe A, Zoico E, Telesca M, Oliso D, Venturi S, Rossi A, Corzato F, Faccioli S, Cominacini L, Santini F, Zamboni M (2013) Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels. doi:10.1007/s00380-012-0315-9
50. Matsuki A, Igawa A, Nozawa T, Nakadate T, Igarashi N, Nonomura M, Inoue H (2006) Early administration of fluvastatin, but not at the onset of ischemia or reperfusion, attenuates myocardial ischemia-reperfusion injury through the nitric oxide pathway rather than its antioxidant property. Circ J 70:1643-1649 (Pubitemid 44819883)
51. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A (2002) Fluvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105:868-873 (Pubitemid 34174929)
52. Suzumura K, Yasuhara M, Tanaka K, Odawara A, Narita H, Suzuki T (1999) An in vivo study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor. Chem Pharm Bull 47:1010-1012 (Pubitemid 29357384)
53. Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S, Hirata Y, Nagai R (2004) Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43:1214-1220 (Pubitemid 38691742)